New Clinical Trial Showed 89.6% Increase in Arterial Elasticity

ABOUT ARTEROSIL®

Arterosil® is an all-natural dietary supplement that has been proven to support the body’s vascular system for optimal function. A new clinical trial showed an 89.6% increase in arterial elasticity following consumption of Arterosil®.

In a previous human clinical study, Arterosil® was demonstrated to help rebuild the endothelial glycocalyx, the micro-thin slippery inner lining that protects all blood vessels. Among other functions, the glycocalyx provides a physical barrier against inadvertent adhesion of platelets and leukocytes to the vascular wall.

That study was conducted with healthy subjects after they consumed a high-sugar meal. The results additionally showed improved endothelial function with Arterosil® supplementation as measured by reactive hyperemia index (RHI).

THE CURRENT STUDY

In the current study, we hypothesized that Arterosil® rapidly improves arterial elasticity and pulse wave reflections through enhancing the endothelial glycocalyx and its mediated arterial function.

Nineteen healthy human subjects (11 females age 22 to 64 and 8 males age 30 to 60) were randomly recruited for the open label clinical study, which was conducted at an independent cardiology center on the Baylor Medical Campus in Plano, Texas.

Their vascular health condition was evaluated by using an FDA approved pulse wave velocity diagnostic device, MaxPulse. The subjects arrived at the clinic in the morning. Their baseline MaxPulse reading was taken at approximately 2 hours (+/- 30 minutes) post consumption of a breakfast of their choice. Immediately after the baseline reading one capsule of ArterosilHP® was swallowed. A post-dose MaxPulse reading was taken every 30 minutes for 3 hours, for a total of 7 MaxPulse readings (baseline, 30 min, 60 min, 90 min, 120 min, 150 min & 180 min +/- 5 minutes). No food or liquid (other than small amounts of water as needed) was consumed during the 3-hour testing period.
During each of the 7 tests for each subject the following data were collected:

- Percentage of Type 1 Wave Forms
- Arterial Elasticity
- Stress Resistance
- Frequency Domain Power

RESULTS

**Percentage of Type 1 Wave Forms:**
Percent of subjects who showed increase: **84.2%**
Average increase: **48.4%** (p = .0032)
Mean time to maximum increase: **114 minutes**

**Arterial Elasticity:**
Percent of subjects who showed increase: **78.9%**
Average increase: **89.6%** (p = .0081)
Mean time to maximum increase: **118 minutes**

**Stress Resistance:**
Percent of subjects who showed increase: **89.5%**
Average increase: **133.3%** (p = .0016)
Mean time to maximum increase: **130 minutes**

**Frequency Domain Power:**
Percent of subjects who showed increase: **84.2%**
Average increase: **37.8%** (p = .0003)
Mean time to maximum increase: **141 minutes**

**Average Percentage Improvement**

**CONCLUSION**

The current clinical study demonstrates that Arterosil® supports arterial health by rapidly improving the body’s percentage of type 1 wave forms, arterial elasticity, stress resistance and frequency domain power: see charts on the following pages.

These findings are consistent with our previous clinical results showing the beneficial effects of Arterosil® on the endothelial glycocalyx and arterial function. Further analysis of these data will help us to understand the mechanisms and to design new studies that evaluate the long-term benefits of Arterosil® supplementation for cardiovascular and microvascular health.
Type 1 Wave Forms by Subject
Average increase: 48.4%
(\( p = .0032 \))

Arterial Elasticity by Subject
Average increase: 89.6%
(\( p = .0081 \))
Frequency Domain Total Power by Subject
Average increase: 37.8%
\((p = .0003)\)

Stress Resistance by Subject
Average increase: 133%
\((p = .0016)\)